2023
SURG-32. EFFICACY OF LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR BIOPSY-PROVEN RADIATION NECROSIS IN RADIOGRAPHICALLY RECURRENT BRAIN METASTASES
Strowd R, Chan M, Tatter S, Chiang V, Fecci P, Prabhu S, Hadjipanayis C, Kirkpatrick J, Sun D, Sinicrope K, Mohammadi A, Sevak P, Abram S, Kim A, Leuthardt E, Chao S, Phillips J, Lacroix M, Williams B, Placantonakis D, Silverman J, Baumgartner J, Piccioni D, Laxton A. SURG-32. EFFICACY OF LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR BIOPSY-PROVEN RADIATION NECROSIS IN RADIOGRAPHICALLY RECURRENT BRAIN METASTASES. Neuro-Oncology 2023, 25: v269-v269. PMCID: PMC10640195, DOI: 10.1093/neuonc/noad179.1031.Peer-Reviewed Original ResearchLaser interstitial thermal therapyKarnofsky performance statusRadiation necrosisInterstitial thermal therapyBrain metastasesRadiographic progressionKaplan-MeierStereotactic radiosurgeryLocal controlMedian Karnofsky performance statusFuture radiographic progressionRadiotherapeutic treatment optionsResults Ninety patientsBrain metastasis patientsMulti-center registryRecurrent brain metastasesMedian hospitalization timeLesional progressionMultivariable FineNinety patientsSymptom controlCumulative incidenceMetastasis patientsPerformance statusSystemic therapyJS09.5.A18F-FLUCICLOVINE PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY: IMAGE INTERPRETATION CRITERIA RESULTS FROM PURSUE, A PROSPECTIVE PHASE 2 TRIAL
Kotecha R, Chiang V, Tom M, Nabavizadeh A, Zan E, Peddi S, Sulman E, Siegel B, Huang J, Brem S, Ware M, Kesari S, Parent E, Pope W, Holmes R, Chau A, Teoh E, Chao S, Aboian M. JS09.5.A18F-FLUCICLOVINE PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY: IMAGE INTERPRETATION CRITERIA RESULTS FROM PURSUE, A PROSPECTIVE PHASE 2 TRIAL. Neuro-Oncology 2023, 25: ii12-ii13. PMCID: PMC10489492, DOI: 10.1093/neuonc/noad137.034.Peer-Reviewed Original ResearchRecurrent brain metastasesImage interpretation criteriaBrain metastasesRadiation therapyLesion uptakeDiagnostic performancePredictive valueProspective phase 2 trialSolid tumor brain metastasesTumor brain metastasesPhase 2 trialInterpretation criteriaNegative predictive valueLow background uptakePositive predictive valueExcellent diagnostic performanceBM recurrencePost-MRIPrimary endpointSecondary endpointsRadiation necrosisReference lesionsUnnecessary surgeryHistopathological analysisInitial cohortNEIM-05 PURSUE: RESULTS FROM A PROSPECTIVE, PHASE 2B TRIAL TO DEFINE IMAGE INTERPRETATION CRITERIA FOR18F-FLUCICLOVINE-PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY
Kotecha R, Chiang V, Tom M, Nabavizadeh A, Zan E, Peddi S, Sulman E, Siegel B, Huang J, Brem S, Ware M, Kesari S, Parent E, Pope W, Holmes R, Chau A, Teoh E, Chao S, Aboian M. NEIM-05 PURSUE: RESULTS FROM A PROSPECTIVE, PHASE 2B TRIAL TO DEFINE IMAGE INTERPRETATION CRITERIA FOR18F-FLUCICLOVINE-PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY. Neuro-Oncology Advances 2023, 5: iii15-iii15. PMCID: PMC10402431, DOI: 10.1093/noajnl/vdad070.057.Peer-Reviewed Original ResearchEvaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.
Kotecha R, Chiang V, Tom M, Nabavizadeh A, Zan E, Peddi S, Sulman E, Siegel B, Huang J, Brem S, Ware M, Kesari S, Parent E, Pope W, Holmes R, Chau A, Teoh E, Chao S, Aboian M. Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial. Journal Of Clinical Oncology 2023, 41: 2001-2001. DOI: 10.1200/jco.2023.41.16_suppl.2001.Peer-Reviewed Original ResearchRecurrent brain metastasesImage interpretation criteriaF-fluciclovine PETF-fluciclovine uptakeBrain metastasesF-fluciclovineRadiation therapyDiagnostic performanceHistopathological analysisSUV maxFirst prospective multicenter trialProspective phase 2 trialSolid tumor brain metastasesTumor brain metastasesPhase 2 trialProspective multicenter trialIndependent blinded readersFluciclovine uptakePost-MRIPrimary endpointSecondary endpointsMulticenter trialRadiation necrosisRecurrent tumorsFuture trialsEfficacy of laser interstitial thermal therapy for biopsy-proven radiation necrosis in radiographically recurrent brain metastases
Chan M, Tatter S, Chiang V, Fecci P, Strowd R, Prabhu S, Hadjipanayis C, Kirkpatrick J, Sun D, Sinicrope K, Mohammadi A, Sevak P, Abram S, Kim A, Leuthardt E, Chao S, Phillips J, Lacroix M, Williams B, Placantonakis D, Silverman J, Baumgartner J, Piccioni D, Laxton A. Efficacy of laser interstitial thermal therapy for biopsy-proven radiation necrosis in radiographically recurrent brain metastases. Neuro-Oncology Advances 2023, 5: vdad031. PMID: 37114245, PMCID: PMC10129388, DOI: 10.1093/noajnl/vdad031.Peer-Reviewed Original ResearchLaser interstitial thermal therapyKarnofsky performance statusRadiation necrosisInterstitial thermal therapyBrain metastasesLocal controlMedian Karnofsky performance statusRecurrent brain metastasesMedian hospitalization timeLow patient morbidityLesional progressionMultivariable FineCumulative incidenceOverall survivalPerformance statusSymptom controlHospitalization timeSystemic therapyMedian timeNeurological deathSymptom managementKaplan-MeierPatient morbiditySeizure prevalenceUS Centers
2022
Combination laser interstitial thermal therapy plus stereotactic radiotherapy increases time to progression for biopsy-proven recurrent brain metastases
Grabowski MM, Srinivasan ES, Vaios EJ, Sankey EW, Otvos B, Krivosheya D, Scott A, Olufawo M, Ma J, Fomchenko EI, Herndon JE, Kim AH, Chiang VL, Chen CC, Leuthardt EC, Barnett GH, Kirkpatrick JP, Mohammadi AM, Fecci PE. Combination laser interstitial thermal therapy plus stereotactic radiotherapy increases time to progression for biopsy-proven recurrent brain metastases. Neuro-Oncology Advances 2022, 4: vdac086. PMID: 35795470, PMCID: PMC9248774, DOI: 10.1093/noajnl/vdac086.Peer-Reviewed Original ResearchLaser interstitial thermal therapyRecurrent brain metastasesBrain metastasis recurrenceKarnofsky performance statusBrain metastasesStereotactic radiotherapyLesion progressionInterstitial thermal therapyMetastasis recurrenceEfficacy of LITTNeuro-Oncology Brain Metastases criteriaSRT failurePercent of patientsAcademic medical centerContrast-enhancing volumeMetastasis (TNM) criteriaOpen resectionPerformance statusProspective trialMedian timeRetrospective studyTumor recurrenceInclusion criteriaMedical CenterEffective treatment
2009
Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients
Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, Bhatt A, Jensen AW, Brown PD, Shih H, Kirkpatrick J, Schwer A, Gaspar LE, Fiveash JB, Chiang V, Knisely J, Sperduto CM, Mehta M. Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients. International Journal Of Radiation Oncology • Biology • Physics 2009, 77: 655-661. PMID: 19942357, DOI: 10.1016/j.ijrobp.2009.08.025.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAnalysis of VarianceBrain NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellCombined Modality TherapyGastrointestinal NeoplasmsHumansKarnofsky Performance StatusKidney NeoplasmsLung NeoplasmsMelanomaMiddle AgedPrognosisRetrospective StudiesSelection BiasSkin NeoplasmsSmall Cell Lung CarcinomaTreatment OutcomeConceptsSignificant prognostic factorsKarnofsky performance statusDiagnosis-specific prognostic factorsNumber of BMSmall cell lung cancerBrain metastasesPrognostic factorsCell lung cancerLung cancerPerformance statusBM patientsRandomized trialsGastrointestinal cancerOnly significant prognostic factorRecurrent brain metastasesFuture randomized trialsRenal cell cancerDS-GPA scoreRenal cell carcinomaExtracranial metastasesMedian survivalCell cancerHistologic typePrognostic indexCell carcinoma